Market View: Big Pharma's Bold Bets, Tung Lok's Recipe for Trouble & Curry’s Candid Confession

What do billion-dollar biotech deals and Stephen Curry’s impostor syndrome have in common? Hosted by Michelle Martin with Ryan Huang, today’s Market View kicks off with two major cancer-fighting pharmaceutical deals—Bristol Myers Squibb teams up with BioNTech while Sanofi acquires Blueprint Medicines. We dive into why Tung Lok’s profits have halved, despite Singapore’s food scene buzzing with new openings and closings. We look at Grab entering the  motor insurance industry and later, Nio, CK Hutchison, and Stamford Land take center stage in our corporate UP or DOWN round-up. Plus, we look at STI movers like DFI Retail, Jardine Matheson, and SGX. And in a surprising twist, NBA star Stephen Curry reveals he still battles impostor syndrome—yes, even champions have doubts.  Companies mentioned: Bristol Myers Squibb, BioNTech, Sanofi, Blueprint Medicines, Tung Lok, Nio, Stamford Land, CK Hutchison, Vodafone, Jardine Matheson, SGX, DFI Retail.  See omnystudio.com/listener for privacy information.